At present,China manages cannabis into industrial and medical types. Industrial cannabis( THC<0. 3%) is grown for fiber and seed,while medical cannabis( THC>0. 3%) is prohibited from being planted and used. In recent years,breakthroughs have been made in the applications for a variety of fields of CBD,a non-psychoactive cannabinoid of Cannabis. However,China made a minimal contribution to this international research hotspot,mainly due to the outdated way of classification on cannabis. Here we reviewed the medicinal use history of cannabis,achievements in the study of Cannabis germplasm,and first proposed the three-level classification of management: psychoactive medicinal cannabis( THC>0. 3%),non-psychoactive medicinal cannabis( THC<0. 3%,high CBD)and industrial cannabis( THC<0. 3%,for fiber and seed,low CBD). Based on summarizing the research progress of the non-psychoactive medicinal cannabis,four key research strategies of breeding,sex control,plant factory,and synthetic biology are proposed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.19540/j.cnki.cjcmm.20190916.101 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Causal associations between immune cells and psychiatric disorders: a bidirectional mendelian randomization analysis.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Graduate School of PLA Medical College, Chinese PLA General Hospital and PLA Medical College, 28 Fu Xing Road, Beijing, 100083, China.
Extensive researches illuminate a potential interplay between immune traits and psychiatric disorders. However, whether there is the causal relationship between the two remains an unresolved question. We conducted a two-sample bidirectional mendelian randomization by utilizing summary data of 731 immune cell traits from genome-wide association studies (GCST90001391-GCST90002121)) and 11 psychiatric disorders including attention deficit/hyperactivity disorder (ADHD), anxiety disorder, autism spectrum disorder (ASD), bipolar disorder (BIP), anorexia nervosa (AN), major depressive disorder (MDD), obsessive-compulsive disorder (OCD), Tourette syndrome (TS), post-traumatic stress disorder (PTSD), schizophrenia (SCZ), and substance use disorders (cannabis) (SUD) from the Psychiatric Genomics Consortium (PGC).
View Article and Find Full Text PDFThe comparative effectiveness of medicinal cannabis for chronic pain versus prescription medication treatment.
Pain
January 2025
Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
Reviews of the effectiveness of medicinal cannabis for chronic pain vary in their conclusions. IASP has identified that a key missing evidence in this debate is data from observational cohort studies, analyzed with comparative effectiveness methods. In a medically supervised context to the use of marijuana for chronic pain, we identified 440 patients certified for medical marijuana by pain specialists in a single healthcare system.
View Article and Find Full Text PDFCannabinoids for Acute Postoperative Pain Management: A Systematic Review and Meta-Analysis of Clinical Trials.
Eur J Pain
March 2025
Universidad del Bosque, Bogotá, Colombia.
Background: Poor acute postoperative pain control, coupled with the use of intravenous medications with a limited and unsafety efficacy spectrum, has led to new therapeutic alternative explorations to reduce adverse events while increasing its analgesic efficacy. There cannabinoids have been proposed as a useful control agent in post-surgical pain. Nevertheless, to date, there is no solid evidence to evaluate them.
View Article and Find Full Text PDFVaping guidance and women's decision-making during pregnancy & postpartum.
Public Health Pract (Oxf)
June 2025
Centre of Excellence for Women's Health, B225-4500 Oak St, Vancouver, BC, V6H 3N1, Canada.
Background: Vaping during pregnancy remains under researched and under reported, making appropriate prevention, health promotion and intervention difficult to design and mount. In this article we assessed the experiences and considerations of women who vape during pregnancy and/or within 2 years post-partum, in order to underpin realistic and informative health information for women and providers in face of conflicting and minimal guidance.
Design: 22 interviews were conducted with pregnant and post-partum women who vape(d) nicotine, cannabis, or both during pregnancy and/or after delivery.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!